中国第三种新冠候选疫苗在後期研究中有效性达66%
巴基斯坦负责国家卫生事务的总理特别助理Faisal Sultan在社交网站上发文指,康希诺生物(06185.HK)的新冠疫苗克威莎TM(ConvideciaTM)在全球开展的多中心三期临床试验的中期数据显示,在巴基斯坦单针接种疫苗28天後,对重症新型冠状病毒肺炎的保护效力为100%,总体保护效力为74.8%。未发生任何与疫苗相关的严重不良反应。
至於基於多个国家的分析,康希诺的疫苗在预防有症状的新冠疫例方面的有效率为65.7%,预防新冠重症病例方面的有效性为90.98%。他写道,全球分析包括3万名参与者和101例新冠确诊病例,但没有透露详细的情况,比如什麽才算是有症状的病例,以及这些病例中哪些算重症病例。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.